Gıancarlo Comı
YOU?
Author Swipe
View article: Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression
Serum Alpha-Linolenic Acid and Long-Term Multiple Sclerosis Activity and Progression Open
Higher serum ALA levels were associated with a lower risk of CDMS, relapses, and disability progression in a large prospective cohort. The results were null or inconsistent for other fatty acids.
View article: Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress
Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress Open
Background: Multiple sclerosis (MS) pathology is characterized by acute and chronic inflammation, demyelination, axonal injury, and neurodegeneration. After decades of research into MS-related degeneration, recent efforts have shifted towa…
View article: Transcorneal Electrical Stimulation Modulates Visual Pathway Function in Mice
Transcorneal Electrical Stimulation Modulates Visual Pathway Function in Mice Open
Due to its ability to modulate neuronal activity, electrical stimulation of the eye may be a promising therapy for preserving or restoring vision. To investigate how electrical currents can influence visual function, Transcorneal Electrica…
View article: The history of the European Neurological Society (1986–2014)—10 years later
The history of the European Neurological Society (1986–2014)—10 years later Open
Background and Purpose The European Academy of Neurology (EAN) was a merger from two parent societies: the European Neurological Association (ENS, founded in 1986) and the European Federation of Neurological Societies (EFNS, founded in 198…
View article: Development and validation of an electronic Symbol‐Digit Modalities Test for remote monitoring of people with multiple sclerosis
Development and validation of an electronic Symbol‐Digit Modalities Test for remote monitoring of people with multiple sclerosis Open
Background Computerized cognitive tests may extend the reach of cognitive screening and monitoring to those with mobility issues or living in remote areas. Moreover, it could enable frequent and autonomous remote cognitive assessments in p…
View article: Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomics
Machine learning-driven diagnosis of multiple sclerosis from whole blood transcriptomics Open
Multiple sclerosis (MS) is a neurological disorder characterized by immune dysregulation. It begins with a first clinical manifestation, a clinically isolated syndrome (CIS), which evolves to definite MS in case of further clinical and/or …
View article: The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care – updates at the 2023 plenary event
The global patient-reported outcomes for multiple sclerosis initiative: bridging the gap between clinical research and care – updates at the 2023 plenary event Open
Significant advancements have been achieved in delineating the progress of the Global PROMS (PROMS) Initiative. The PROMS Initiative, a collaborative endeavor by the European Charcot Foundation and the Multiple Sclerosis International Fede…
View article: Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review
Managing multiple sclerosis in individuals aged 55 and above: a comprehensive review Open
Multiple Sclerosis (MS) management in individuals aged 55 and above presents unique challenges due to the complex interaction between aging, comorbidities, immunosenescence, and MS pathophysiology. This comprehensive review explores the ev…
View article: Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI
Central vein sign and trigeminal lesions of multiple sclerosis visualised by 7T MRI Open
Background Although trigeminal nerve involvement is a characteristic of multiple sclerosis (MS), its prevalence across studies varies greatly due to MRI resolution and cohort selection bias. The mechanism behind the site specificity of tri…
View article: Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a <i>post hoc</i> analysis
Serum neurofilament light chain correlations in patients with a first clinical demyelinating event in the REFLEX study: a <i>post hoc</i> analysis Open
Background: In REFLEX, subcutaneous interferon beta-1a (sc IFN β-1a) delayed the onset of multiple sclerosis (MS) in patients with a first clinical demyelinating event (FCDE). Objectives: This post hoc analysis aimed to determine whether b…
View article: Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force
Introducing a core dataset for real-world data in multiple sclerosis registries and cohorts: Recommendations from a global task force Open
Background: As of September 2022, there was no globally recommended set of core data elements for use in multiple sclerosis (MS) healthcare and research. As a result, data harmonisation across observational data sources and scientific coll…
View article: Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial
Concurrent administration of serotonergic antidepressants and ozanimod in participants with relapsing multiple sclerosis from the open-label extension DAYBREAK trial Open
Background: Monoamine oxidase (MAO) inhibitors can interact with selective serotonin reuptake inhibitors (SSRIs)/serotonin–norepinephrine reuptake inhibitors (SNRIs). There is clinical interest surrounding use of ozanimod with SSRIs/SNRIs …
View article: Optical coherence tomography with voxel-based morphometry: a new tool to unveil focal retinal neurodegeneration in multiple sclerosis
Optical coherence tomography with voxel-based morphometry: a new tool to unveil focal retinal neurodegeneration in multiple sclerosis Open
Neurodegeneration is the main contributor to disability accumulation in multiple sclerosis. Previous studies in neuro-ophthalmology have revealed that neurodegeneration in multiple sclerosis also affects the neuro-retina. Optical coherence…
View article: Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury
Development and multi-center validation of a fully automated digital immunoassay for neurofilament light chain: toward a clinical blood test for neuronal injury Open
Objectives Neurofilament light chain (NfL) has emerged as a promising biomarker for detecting and monitoring axonal injury. Until recently, NfL could only be reliably measured in cerebrospinal fluid, but digital single molecule array (Simo…
View article: Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis
Automatic Assessment of the 2-Minute Walk Distance for Remote Monitoring of People with Multiple Sclerosis Open
The aim of this study was to investigate the feasibility of automatically assessing the 2-Minute Walk Distance (2MWD) for monitoring people with multiple sclerosis (pwMS). For 154 pwMS, MS-related clinical outcomes as well as the 2MWDs as …
View article: Visual evoked potentials waveform analysis to measure intracortical damage in a preclinical model of multiple sclerosis
Visual evoked potentials waveform analysis to measure intracortical damage in a preclinical model of multiple sclerosis Open
Introduction Visual evoked potentials (VEPs) are a non-invasive technique routinely used in clinical and preclinical practice. Discussion about inclusion of VEPs in McDonald criteria, used for Multiple Sclerosis (MS) diagnosis, increased t…
View article: HNF4α, SP1 and c-myc are master regulators of CNS autoimmunity
HNF4α, SP1 and c-myc are master regulators of CNS autoimmunity Open
Hepatocyte nuclear factor 4 α (HNF4α), a transcription factor (TF) essential for embryonic development, has been recently shown to regulate the expression of inflammatory genes. To characterize HNF4a function in immunity, we measured the e…
View article: Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis
Autonomic response to walk tests is useful for assessing outcome measures in people with multiple sclerosis Open
Objective: The aim of this study was to evaluate the association between changes in the autonomic control of cardiorespiratory system induced by walk tests and outcome measures in people with Multiple Sclerosis (pwMS). Methods: Electrocard…
View article: Editorial: Fatigue in multiple sclerosis—A current perspective
Editorial: Fatigue in multiple sclerosis—A current perspective Open
EDITORIAL article Front. Neurol., 07 February 2023Sec. Multiple Sclerosis and Neuroimmunology Volume 14 - 2023 | https://doi.org/10.3389/fneur.2023.1150717
View article: Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach
Combining Clinical and Genetic Data to Predict Response to Fingolimod Treatment in Relapsing Remitting Multiple Sclerosis Patients: A Precision Medicine Approach Open
A personalized approach is strongly advocated for treatment selection in Multiple Sclerosis patients due to the high number of available drugs. Machine learning methods proved to be valuable tools in the context of precision medicine. In t…
View article: Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study
Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study Open
Background Sleep disorders are common in patients with multiple sclerosis and have a bidirectional interplay with fatigue and depression. Objective To evaluate the effect of treatment with oral dimethyl fumarate on the quality of sleep in …
View article: Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study
Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study Open
Background and objectives: Alemtuzumab demonstrated superior efficacy versus subcutaneous interferon (IFN) beta-1a in participants with relapsing-remitting multiple sclerosis in the 2-year CARE-MS I and II trials. Efficacy was maintained i…